Literature DB >> 24094543

Eosinophilic asthma: insights into the effects of reducing IL-5 receptor-positive cell levels.

Amal H Assa'ad1, Marc E Rothenberg.   

Abstract

Entities:  

Keywords:  Eosinophils; IL-5; anti–IL-5; anti–IL-5 receptor; benralizumab; steroid-dependent asthma

Mesh：

Substances：

Year:  2013        PMID： 24094543      PMCID： PMC4140088          DOI： 10.1016/j.jaci.2013.08.036

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  5 in total

1.  An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.

Authors:  Amal H Assa'ad; Sandeep K Gupta; Margaret H Collins; Mike Thomson; Amy T Heath; Deborah A Smith; Teresa L Perschy; Cynthia H Jurgensen; Hector G Ortega; Seema S Aceves
Journal:  Gastroenterology       Date:  2011-08-09       Impact factor: 22.682

2.  Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Jonathan M Spergel; Marc E Rothenberg; Margaret H Collins; Glenn T Furuta; Jonathan E Markowitz; George Fuchs; Molly A O'Gorman; Juan Pablo Abonia; James Young; Timothy Henkel; H Jeffrey Wilkins; Chris A Liacouras
Journal:  J Allergy Clin Immunol       Date:  2011-12-28       Impact factor: 10.793

3.  Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.

Authors:  Mario Castro; Sameer Mathur; Frederick Hargreave; Louis-Philippe Boulet; Fang Xie; James Young; H Jeffrey Wilkins; Timothy Henkel; Parameswaran Nair
Journal:  Am J Respir Crit Care Med       Date:  2011-08-18       Impact factor: 21.405

4.  Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma.

Authors:  William W Busse; Rohit Katial; David Gossage; Suha Sari; Bing Wang; Roland Kolbeck; Anthony J Coyle; Masamichi Koike; George L Spitalny; Peter A Kiener; Gregory P Geba; Nestor A Molfino
Journal:  J Allergy Clin Immunol       Date:  2010-06       Impact factor: 10.793

5.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.

Authors:  Michel Laviolette; David L Gossage; Gail Gauvreau; Richard Leigh; Ron Olivenstein; Rohit Katial; William W Busse; Sally Wenzel; Yanping Wu; Vivekananda Datta; Roland Kolbeck; Nestor A Molfino
Journal:  J Allergy Clin Immunol       Date:  2013-07-16       Impact factor: 10.793
  5 in total
  4 in total

1.  Clinical efficacy of implementing Bio Immune(G)ene MEDicine in the treatment of chronic asthma with the objective of reducing or removing effectively corticosteroid therapy: A novel approach and promising results.

Authors:  Gilbert Glady
Journal:  Exp Ther Med       Date:  2018-04-02       Impact factor: 2.447

2.  Advances in pediatric asthma in 2013: coordinating asthma care.

Authors:  Stanley J Szefler
Journal:  J Allergy Clin Immunol       Date:  2014-03       Impact factor: 10.793

Review 3.  Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.

Authors:  Corrado Pelaia; Alessandro Vatrella; Andrea Bruni; Rosa Terracciano; Girolamo Pelaia
Journal:  Drug Des Devel Ther       Date:  2018-03-21       Impact factor: 4.162

Review 4.  Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.

Authors:  Corrado Pelaia; Cecilia Calabrese; Alessandro Vatrella; Maria Teresa Busceti; Eugenio Garofalo; Nicola Lombardo; Rosa Terracciano; Girolamo Pelaia
Journal:  Biomed Res Int       Date:  2018-05-10       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.